Australian Respiratory Council
Untitled Document
  • Laboratory safety Global Edition 2019

    The Laboratory Safety Handbook is an initiative of a Working Group of the Stop TB Partnership in collaboration with the Global Laboratory Initiative. The handbook has been developed to help reduce the risk of infection or injury, and protect the laboratory workforce and the wider community against unintentional exposures or releases of pathogenic biological agents. This handbook provides practical information and clear illustrations to assist laboratory staff in understanding the important safety issues related to the processing and management of samples potentially containing Mycobacterium tuberculosis.

  • Pacific Islands TB Controllers Association (PITCA) Conference

    Register now for the Pacific Islands TB Controllers Association (PITCA) Conference
    Date:September 9-13, 2019
    Location:Palasia Hotel, Koror, Palau

    This conference will cover various aspects of TB diagnosis, treatment, and care that is relevant to the Pacific Islands region. The format will include plenary sessions for general information and four tracks for more tailored learning. Participants can choose from these four tracks: clinical, laboratory, nursing and outreach, and program manager.

    Target Audience: Physicians, nurses, outreach workers, program managers, laboratory staff, and other healthcare professionals who are involved in the care of persons with TB infection or TB disease are welcome to attend.

    Conference Website:

  • WORLD TB DAY – 24TH MARCH 2019

    World TB Day is on 24 March 2019 will shine a spotlight on tuberculosis (TB). This date marks the day in 1882 when Dr Robert Koch, the founder of modern bacteriology, declared that he had discovered the bacterium that causes TB.

  • UN HLM ON TB Live from New York

    The historic UN High-Level Meeting on TB has convened in New York City, in the UN Headquarters.
    Watch it LIVE


    The latest report from the Treatment Action Group (TAG) and the Stop TB Partnership, on global funding trends for TB research and development (R&D), presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.

    The report—Tuberculosis Research Funding Trends, 2005–2018—is a critical accountability tool and serves as a barometer of progress in raising support for the scientific innovation needed to eliminate TB.

    Global TB research funding totaled US$906 million in fiscal year 2018, an increase of $134 million from 2017. This is the highest level of funding ever recorded by TAG. TB scientists and their advocates should feel encouraged by three back-to-back years of increasing investments from 2016 to 2018. However, the 2018 funding figure still falls more than half-way short of the US$2 billion annual target set at 2018’s United Nations High Level Meeting on TB.

    “The US$134 million increase in TB research funding is cause for celebration and shows that the tireless efforts of TB partners around the world are getting results,” said Lucica Ditiu, Executive Director of the Stop TB Partnership. “But this still leaves us short of the US$2 billion annual funding figure endorsed at the UN High-Level Meeting. Because we're off track, we'll now need to spend more each year to make up the deficit. We can’t afford to coast on recent momentum if we are serious about ending TB—it’s time to put our money where our mouths are”.

  • Launch of the updated Global Plan to End TB: 2018-2022; from L-R: Lucica Ditiu, Executive Director, Suvanand Sahu, Deputy Executive Director, The Stop TB Partnership, Luiz Henrique Mandetta, MoH Brazil and Chair of the Stop TB Partnership Board, Paula Fujiwara, Scientific Director, The Union


    Geneva/Jakarta. 10 December 2019 —The Stop TB Partnership today launched the updated Global Plan to End TB 2018-2022, which calls for 2.6 billion USD per year for vital research and development of new tuberculosis (TB) diagnostic tools, new drug regimens and a new vaccine, and 13 billion USD per year for TB care and prevention.

    If the updated Global Plan is fully funded and implemented, countries will reach UNHLM on TB treatment targets set for 2022, including putting 40 million people on treatment for TB, including 3.5 million children and 1.5 million people with drug-resistant TB. This will lead to 1.5 million fewer deaths due to TB, and the return on investment will be 44 USD for 1 USD spent. On the other hand, a five-year delay in increasing funding for TB research and development would lead to approximately 2 million more people dying and an additional 13.9 million people developing TB.

    Dr Luiz Mandetta, Brazil Minister of Health and Chairperson of the Stop TB Partnership Board"The coming three years, up to 2022, will be important for the TB Community at large. This is when we make it or break it. The good news is that we have what is needed to make it, including country targets as shares of the UNHLM TB targets. As incoming chairperson of the Stop TB Board, I will do my best to have this plan implemented, executed & funded." Dr Luiz Mandetta, Brazil Minister of Health and Chairperson of the Stop TB Partnership Board.

  • Donate Now towards a community free of respiratory disease

    The Impact of TB

    Each year there are:
    • √ 10 million people diagnosed with TB
    • √ 1.5 million deaths from the disease
    • √ 3.5 million people are not diagnosed or not treated
    • √ Vulnerable children, women, the very poor, those infected with HIV/AIDS, indigenous populations and the elderly who do not receive the diagnosis or treatment to cure TB
    • √ 1 million children become ill with TB
    • √ 230,000 children die from TB.

    We need your support now more than ever to

    Educate communities and train health workers
    Fund Research
    Develop educational resources

  • Nontuberculous Mycobacteria brochure

  • G20 Leaders Elevate TB challenge to Heads of State Level

    Unprecedented momentum towards ending AMR and TB crisis

  • Our Patron, the Governor of New South Wales, is now on Facebook.

    We invite you to follow and like the Governor’s page which will give a glimpse into the role of the Governor, provide a window into the activities of Government House Sydney and highlight the work of the many Patronage groups who, like us, are making a difference in New South Wales.

  • Exploring Women's Experience of TB in East Kwaio, Solomon Islands: a short movie

  • ACTnet Group


    Give a gift to ARC. Every donation makes a difference.

  • A Century of Service

    100 Years of advocacy and commitment to Tuberculosis and Lung Health.

  • Our Work

    Supporting community based activities, health care worker training and program capacity building.

  • Investing in the future

    ARC is committed to funding research activity in TB and respiratory disease

  • Resources

    Development of resources to raise awareness about TB within the community to meet the training needs of nurses and health workers


We Need Your Support

Donate Now

Donate Now

Where We Work

Where We Work

World TB Day

World TB Day

Welcome to the Australian Respiratory Council


David MacintoshThe Australian Respiratory Council (ARC) has a distinguished history as an advocate and champion for public health initiatives. Throughout the last century, ARC has established a role and profile as an organisation that has successfully engaged civil society, academics, researchers, government and industry to bring focus to investment in our agency’s mission and vision; to develop and support innovative and effective approaches to research and development in lung health and to improve lung health in communities, with an emphasis on disadvantaged groups.

In partnership with leading local and global agencies, ARC has been able to contribute to health care worker training and development, program capacity building, implementation of community based approaches to improving lung health and support for communities in need both within Australia and across the region. Through the development of partnerships and by initiating or adding value to programs and projects that contribute to respiratory health, a small agency can make a difference.

ARC continues to provide seed funding for leading researchers to initiate new projects directed towards improving health care for tuberculosis and other respiratory diseases. Research is vital in discovering new approaches to early diagnosis of disease, developing new drugs and evaluating new programs for effective disease management.

ARC continues to develop projects in partnership with aligned organisations to improve respiratory health in disadvantaged communities, such as Indigenous Australians. The ARC is also committed to working in collaboration with health care workers in the Pacific Islands and with our Asia Pacific neighbours to assist in developing programs for the diagnosis and management of tuberculosis (TB) and other respiratory diseases.